HIGH-ACTIVITY I-125 INTERSTITIAL IRRADIATION IN THE TREATMENT OF PEDIATRIC CENTRAL-NERVOUS-SYSTEM TUMORS - A PILOT-STUDY

被引:4
|
作者
FONTANESI, J
HEIDEMAN, RL
MUHLBAUER, M
MULHERN, R
SANFORD, RA
DOUGLASS, EC
KOVNAR, E
OCHS, JJ
KUTTESCH, JF
TAI, D
KUN, LE
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38105 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA
[3] ST JUDE CHILDRENS RES HOSP, DEPT NEUROL, MEMPHIS, TN 38105 USA
[4] ST JUDE CHILDRENS RES HOSP, DIV BEHAV MED, MEMPHIS, TN 38105 USA
[5] UNIV TENNESSEE, COLL MED, DEPT RADIOL, MEMPHIS, TN USA
[6] UNIV TENNESSEE, COLL MED, DEPT NEUROSURG, MEMPHIS, TN USA
[7] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA
[8] ST CHRISTOPHERS HOSP CHILDREN, PHILADELPHIA, PA 19133 USA
关键词
I-125; BRAIN TUMORS; INTERSTITIAL IMPLANTS; PEDIATRIC TUMORS;
D O I
10.1159/000120918
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Malignant pediatric tumors of the central nervous system (CNS) have a poor prognosis, with local failure rates as high as 50%, In an attempt to improve local tumor control, we used stereotactic interstitial therapy with I-125 implants in patients with recurrent/secondary or newly diagnosed CNS malignancies, Catheters were placed using computed tomography (CT) guidance; computerized dosimetry was completed with the aid of orthogonal films. Implants delivered 1,000 cGy/day to the tumor periphery (0.5 cm beyond the boundary of enhancement on CT scans), to a total dose of 60 Gy, Hyperfractionated external beam irradiation (HEBI), started 2-4 weeks after removal of implants, delivered total doses of 66-70.4 Gy in 110-cGy fractions twice daily to a 3-cm margin around the implant volume, Eight of the 1 1 patients with newly diagnosed tumors also received 48.4 Gy HEBI to the craniospinal axis. Tumor regression was noted at 2 months after implantation in the 4 patients treated for recurrent/secondary tumors; local progression was subsequently documented in 2 cases at 6 and 20 months after implantation, while a third patient died 6 months after implantation with no evidence of local recurrence. The remaining recurrent/secondary tumor patient has no evidence of active recurrence 15 months after implantation. Local control was maintained in 9 of the 1 1 patients treated for primary tumors for a median of 27 months (range 15 to 48+ months). The two local failures occurred at 5 and 7 months after implantation. Six patients are alive without evidence of progressive disease (median = 23 months after implantation), There were no severe acute toxicities, but 7 patients later developed histologically confirmed tumor necrosis, Quality of life assessment (QLA) following initial primary therapy with implantation was evaluated utilizing an established criteria and found to be excellent with only one child showing marked QLA score decrease which was related to neurosurgical intervention for radiation-induced necrosis and dysfunctional family social situation, This small series suggests that stereotactic I-125 implantation followed by HEBI merits further evaluation in selected children with supratentorial malignant lesions.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 50 条
  • [2] STEREOTAXIC INTERSTITIAL BRACHYTHERAPY OF MALIGNANT BRAIN-TUMORS WITH REMOVABLE HIGH-ACTIVITY I-125 (I-125)
    GUTIN, PH
    LEIBEL, SA
    JOURNAL OF NEURO-ONCOLOGY, 1986, 4 (01) : 111 - 111
  • [3] HIGH-ACTIVITY I-125 INTERSTITIAL IMPLANT FOR GLIOMAS
    SCHARFEN, CO
    SNEED, PK
    WARA, WM
    LARSON, DA
    PHILLIPS, TL
    PRADOS, MD
    WEAVER, KA
    MALEC, M
    ACORD, P
    LAMBORN, KR
    LAMB, SA
    HAM, B
    GUTIN, PH
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (04): : 583 - 591
  • [4] HIGH-ACTIVITY I-125 ENDOCURIETHERAPY FOR HEAD AND NECK TUMORS
    KUMAR, PP
    GOOD, RR
    YONKERS, AJ
    OGREN, FP
    LARYNGOSCOPE, 1989, 99 (02): : 174 - 178
  • [5] INTERSTITIAL BRACHYTHERAPY WITH REMOVABLE HIGH-ACTIVITY I-125 SOURCES FOR RECURRENT MALIGNANT BRAIN-TUMORS
    LEIBEL, SA
    GUTIN, PH
    PHILLIPS, TL
    WARA, WM
    WEAVER, KA
    LAMB, S
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1985, 8 (01): : 20 - 20
  • [6] RECURRENT MALIGNANT GLIOMAS - SURVIVAL FOLLOWING INTERSTITIAL BRACHYTHERAPY WITH HIGH-ACTIVITY I-125 SOURCES
    GUTIN, PH
    LEIBEL, SA
    WARA, WM
    CHOUCAIR, A
    LEVIN, VA
    PHILIPS, TL
    SILVER, P
    DASILVA, V
    EDWARDS, MSB
    DAVIS, RL
    WEAVER, KA
    LAMB, S
    JOURNAL OF NEUROSURGERY, 1987, 67 (06) : 864 - 873
  • [7] Long-term follow-up after high-activity I-125 brachytherapy for pediatric brain tumors
    Sneed, PK
    Russo, C
    Scharfen, CO
    Prados, MD
    Malec, MK
    Larson, DA
    Lamborn, KR
    Lamb, SA
    Voss, B
    Weaver, KA
    Phillips, TL
    Gutin, PH
    Wara, WM
    Edwards, MSB
    PEDIATRIC NEUROSURGERY, 1996, 24 (06) : 314 - 322
  • [8] EXTERNAL IRRADIATION FOLLOWED BY AN INTERSTITIAL HIGH-ACTIVITY I-125 IMPLANT BOOST IN THE INITIAL TREATMENT OF MALIGNANT GLIOMAS - NCOG STUDY 6G-82-2
    GUTIN, PH
    PRADOS, MD
    PHILLIPS, TL
    WARA, WM
    LARSON, DA
    LEIBEL, SA
    SNEED, PK
    LEVIN, VA
    WEAVER, KA
    SILVER, P
    LAMBORN, K
    LAMB, S
    HAM, B
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (03): : 601 - 606
  • [9] SPECIFIC I-125 ENDOTHELIN-1 BINDING-SITES IN THE CENTRAL-NERVOUS-SYSTEM
    NIWA, M
    KAWAGUCHI, T
    YAMASHITA, K
    MAEDA, T
    KURIHARA, M
    KATAOKA, Y
    OZAKI, M
    CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1991, 13 (05) : 799 - 806
  • [10] AUTORADIOGRAPHIC DISTRIBUTION OF I-125 GALANIN BINDING-SITES IN THE RAT CENTRAL-NERVOUS-SYSTEM
    SKOFITSCH, G
    SILLS, MA
    JACOBOWITZ, DM
    PEPTIDES, 1986, 7 (06) : 1029 - 1042